부산광역시내과

2026 대한조혈모세포이식학회 국제학술대회(ICBMT 2026) - 9월 19일(3일차)

Name: 2026 대한조혈모세포이식학회 국제학술대회(ICBMT 2026) - 9월 19일(3일차)
Start: 2026-09-19
End: 2026-09-19
Location: 벡스코

2.0점 일반 2.0

주최: 대한조혈모세포이식학회
일자: 2026-09-19
장소: 벡스코
수강료: 200,000원 구분별

수강료 구분별 상세보기

회원 150,000원, 비회원 200,000원, 기타 80,000원

원문 기준 · 정확한 등록비는 KMA 신청 페이지에서 확인하세요.

평점 구성

총 평점2.0점

필수평점0점

일반평점2.0점

연수평점은 3년 24점·연 8점 상한·필수 2점 요건이 있습니다. 이 행사 들으면 올해 상한까지 몇 점? →

KMA 등록 페이지에서 신청 → 평점 계산기

세부 일정 (24강)

08:30~09:00 Ph-positive ALL in 2026: From Precision Immuno-targeted Therapy to Transplantation Room C Jae-Ho Yoon(College of Medicine, The Catholic University of Korea)
09:00~09:30 Hepatic, Pulmonary, and Systemic Endothelial Injury after Allogeneic HSCT: SOS/VOD, Capillary Leak/Engraftment Syndrome, and IPS/DAH Room A Hakan Göker(Hacettepe University)
09:30~10:00 Microvascular and CNS Endothelial Dysfunction (TA-TMA, PRES, GVHD-Related Endothelial Injury) Room A Suhyun Yoon(Korea University College of Medicine)
09:00~09:10 [구연발표]Longitudinal Immune Reconstitution and Viral Landscape Under Letermovir Prophylaxis in Pediatric Allogeneic HSCT Room C Qingwei Wang(Childrens Hospital of Soochow University)
09:10~09:20 [구연발표]Outcomes of ex vivo T cell depleted haploidentical HSCT in children with acute lymphoblastic leukemia Room C Sung Han Kang(Asan Medical Center Childrens Hospital, University of Ulsan College of Medicine)
09:20~09:30 [구연발표]Comparative Outcomes of Carboplatin-Etoposide-Melphalan and Busulfan-Melphalan as High-Dose Chemotherapy for High-Risk Neuroblastoma: An International Two-Center Study from Taiwan and Korea Room C Jin Kyung Suh(Asan Medical Center Children)
09:30~09:40 [구연발표]Real-World Outcomes Of Chimeric Antigen Receptor T-Cell Therapy In Pediatric B-Cell Acute Lymphoblastic Leukemia: Role Of Consolidative Hematopoietic Cell Transplantation Room C Jae Won Yoo(Seoul St. Marys Hospital, College of Medicine, The Catholic University of Korea)
09:40~09:50 [구연발표]Haploidentical Transplantation with Unrelated Cord Blood Support (SZ-19-TM Protocol) Improves Outcomes in Pediatric Transfusion-Dependent Thalassemia: A Large-Scale Retrospective Cohort Study Room C Ruihao Zheng(Shenzhen Childrens Hospital)
09:50~10:00 [구연발표]Pre-freezing Hematocrit Independently Associated with Post-thaw CD34+ Cell Viability in Cryopreserved Autologous Peripheral Blood Stem Cell Products from Pediatric Neuroblastoma Patients Room C Thi Thanh Lam Nguyen(National Childrens hospital)
09:00~09:10 [구연발표]Single-Cell Transcriptomic and TCR Repertoire Profiling Defines an Exhaustion-Associated CD39+ CD8+ T-Cell State in the Bone Marrow of Acute Lymphoblastic Leukemia Room D Nayeon Seong(The Catholic University of Korea, Ajou University School of Medicine)
09:10~09:20 [구연발표]Assessment of CRS-Related Toxicity of BCMA CAR-MILs Using the NSG-SGM3 Model Room D Manh Cuong Vo(Chonnam National University Hwasun Hospital, Vaxcell-Bio)
09:20~09:30 [구연발표]First Korean Report of Donor-Derived Multivirus-Specific T-Cell Therapy for Refractory BK Virus Hemorrhagic Cystitis after Pediatric Haploidentical Hematopoietic Cell Transplantation Room D Jae Won Yoo(Seoul St. Marys Hospital, College of Medicine, The Catholic University of Korea)
09:30~09:40 [구연발표]Development of Bispecific CAR- T Cells Targeting Mesothelin (MSLN) and Disialoganglioside 2 (GD2) for Neuroblastoma Room D Nayoung Kim(Asan Medical Center)
09:40~09:50 [구연발표]First-in-Human Phase 1 Study of GF-CART01, a Non-Viral CD19/CD20 Dual-Targeting CAR T Generated Using the qCART Platform in Relapsed/Refractory B-Cell Malignancies Room D Shang-Ju Wu(National Taiwan University Hospital)
09:50~10:00 [구연발표]Exploring the Therapeutic Potential of CAR-MSCs Targeting the OX40/OX40L Axis in Immune Disorders Room D Byungchan Kim(Samsung Medical Center, Sungkyunkwan University)
10:00~10:10 휴식 ()
10:10~10:40 Pediatric Chronic GVHD: From Biological Insights to Clinical Management Room A Kirk Schultz(BC Childrens Hospital Research Insitutue)
10:40~11:10 Immunobiology of GVHD Prevention Room A Takanori Teshima(Hokkaido University)
11:10~11:40 Microbiome and GvHD Following Allogeneic HSCT Room A Yoo Jin Lee(University of Ulsan College of Medicine)
10:10~10:40 Integrating MRD into CAR T-cell Therapy for ALL: from Patient Selection to Post-treatment Intervention Room C Jae Park(Memorial Sloan Kettering Cancer Center)
10:40~11:10 Sequencing Cellular Therapy in Multiple Myeloma: Lessons from Trials and Real-world Practice Room C Binod Dhakal(Medical College of Wisconsin)
11:10~11:40 Real-world CAR‑T Experience in LBCL Room C Young Woo Jeon(The Catholic University of Korea)
10:10~10:40 Radiotherapy in Hematologic Malignancies and Stem Cell Transplantation Room D Yang-Gun Suh(National Cancer Center)
10:40~11:10 Restoring Normal life for Hematology Patients Room D Kwang-Sung Kim(College of Medicine, The Catholic University of Korea)